Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $19740 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 12,000 times a week, but only 140 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$0 of $19740 - as of 2023-01-03
0%
Header Image
Reboxitin in ADHD

Sitemap

Reboxitin in ADHD

Reboxitin is a norepinephrine reuptake inhibitor, alongside weak serotonin reuptake inhibition.

Trade names: Edronax (D, CH, A), Solcenx (D)

Reboxitin is a noradrenergic drug that has been reported to be effective in ADHD. As an antidepressant, as it was actually intended, it was probably quite unsuccessful.

The updated European Consensus on the Diagnosis and Treatment of ADHD (2018) identifies reboxitine as a possible alternative to atomoxetine in ADHD.1

Reboxitin could be used primarily in adults without comorbidities.23